IDENTIFY: Non-invasive Point-of-care Diagnosis Using Machine Learning and Signal Analytics to Transform Early Detection of Heart Disease

Sponsor
Analytics For Life (Industry)
Overall Status
Recruiting
CT.gov ID
NCT03864081
Collaborator
(none)
2,500
1
1
42.7
58.6

Study Details

Study Description

Brief Summary

This study is designed as a repository study to collect resting cardiac phase signals and subject meta data from eligible subjects using the Phase Signal Recorder (PSR) prior to coronary angiography. The repository data will be used for the purposes of research, development, optimization and testing of machine-learning algorithms developed by Analytics 4 Life.

Condition or Disease Intervention/Treatment Phase
  • Device: Phase Signal Recorder
N/A

Detailed Description

Male and Female subjects will be uniquely and consecutively enrolled into one of two groups to support populating a repository of phase signals: Group 1: Subjects with known prior coronary artery disease or previous percutaneous coronary intervention (PCI), and Group 2: Subjects with new onset symptoms suggestive of obstructive coronary artery disease at current presentation with no known coronary artery disease.

Enrollment into Group 1 and Group 2 will occur simultaneously until up to 500 male subjects and up to 1000 female subjects with paired data (phase signal and coronary angiography outcomes data) are enrolled. Once the desired number of subjects have been enrolled from both groups, then only Group 2 will continue to be enrolled.

Resting phase signals will be collected in all patients who meet inclusion/exclusion criteria and have signed an informed consent form. This study consists of a screening visit, resting phase signal collection (study procedure), and coronary angiography. In this study, resting phase signals will be acquired in subjects prior to coronary angiography.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
2500 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Non-Invasive Point-of-care Diagnosis Using Machine Learning and Signal Analytics to Transform Early Detection of Heart Disease
Actual Study Start Date :
Dec 10, 2018
Anticipated Primary Completion Date :
Jul 1, 2022
Anticipated Study Completion Date :
Jul 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Other: Enrolled Subjects (PSR)

Patients who meet the study's inclusion and exclusion criteria, including signing the informed consent form, subjects will undergo signal acquisition prior to their scheduled cardiac catheterization on the day of the procedure.

Device: Phase Signal Recorder
The Phase Signal Acquisition (PSAQ) System is a medical device system that is being developed to collect phase signals from patients to support the development and testing of machine learned algorithms. The PSAQ System consists of two components that work together to acquire and transmit the phase signals and patient specific data to a secured, cloud-based repository. The PSAQ System is comprised of: 1) the Phase Signal Recorder (PSR) which is a portable instrument, and 2) the Phase Signal Data Repository (PSDR) which is a cloud based data repository. Data collected during this study will not be used to guide treatment.
Other Names:
  • PSR
  • Outcome Measures

    Primary Outcome Measures

    1. Phase Signal Recorder Procedure [7 day]

      Resting phase signals will be collected from eligible subjects prior to coronary angiography and paired with angiography results..

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    21 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Patients ≥ 18 years old;

    2. Symptoms suggestive of obstructive CAD;

    3. Scheduled to undergo cardiac catheterization with coronary angiography;

    4. Ability to understand the requirements of the study and to provide written informed consent.

    Exclusion Criteria:
    1. Prior documented history of myocardial infarction (MI);

    2. Suspected acute myocardial infarction (AMI) at current presentation;

    3. Prior coronary artery bypass grafting (CABG);

    4. Prior heart valve replacement;

    5. Previous sustained or paroxysmal atrial or ventricular arrythmia;

    6. Infiltrative myocardial disease (amyloid, sarcoid, right ventricular dysplasia);

    7. Presence of cardiac implantable electronic device (CIED), including implantable cardioverter defibrillator (ICD), pacemaker (PM), implantable loop recorders and other monitors;

    8. Implantable Neuro-stimulators;

    9. Congenital Heart Disease;

    10. Pregnant or breast feeding;

    11. Currently taking any Type IA, IC or III antiarrhythmics;

    12. Any history of amiodarone use;

    13. Clinically significant chest deformity (e.g., pectus excavatum or pectus carinatum);

    14. Breast implants;

    15. Neuromuscular Disease if the condition results in tremor or muscle fasciculations.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Atlanta Heart Specialists Cumming Georgia United States 30041

    Sponsors and Collaborators

    • Analytics For Life

    Investigators

    • Study Director: William E Sanders, Jr., MD JD LLM MBA FHRS, Analytics For Life

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Analytics For Life
    ClinicalTrials.gov Identifier:
    NCT03864081
    Other Study ID Numbers:
    • CADF-CIP-001
    First Posted:
    Mar 6, 2019
    Last Update Posted:
    Jan 24, 2022
    Last Verified:
    Dec 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    Yes
    Keywords provided by Analytics For Life
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 24, 2022